About
FEMSelect is a women-led medical technology company focused on innovative solutions for pelvic organ prolapse (POP), a condition that affects many women, especially those over 50. The company aims to enhance women's health by providing advanced, minimally invasive technologies that improve patient outcomes and shorten recovery times. The flagship product, the EnPlace system, is a patented, meshless medical device designed for pelvic organ prolapse repair. This procedure is minimally invasive, typically completed in about 30 minutes, and can often be performed as a same-day surgery. The EnPlace system has received FDA 510(k) clearance and the CE Mark in the European Union, indicating its regulatory approval for clinical use. Clinical studies show that it offers sustainable long-term success while reducing recovery time and medical costs compared to traditional surgeries. FEMSelect's leadership team has extensive experience in women's health and healthcare commercialization. The company has relocated its headquarters to the United States to better serve its largest market and expand international partnerships.
Technologies
Keywords
Company Information
-
Employees 17
-
Founded 2012
-
Annual Revenue $10200000
-
Total Funding $12000000
Location
2 HaMa'ayan Street, Modi'in-Maccabim-Re'ut, Center District, Israel, 7177871